CBF/GLIS2 Pediatric AML | Clinical Trials Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

27,170 results for “CBF/GLIS2 Pediatric AML”

Need more precision?

Filter by phase, recruitment status, country, sponsor, age, and study type.

Refine trial search

ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML

First posted Nov 18, 2022

Timed-Sequential Induction in CBF-AML

200 participants · First posted Jan 30, 2007

Avapritinib in CBF-AML With KIT Mutations

50 participants · First posted Apr 20, 2023

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

50 participants · First posted Mar 19, 2024

The Efficacy of Allo-HSCT in ND HR-CBF-AML

90 participants · First posted Jun 13, 2024

Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML

68 participants · First posted Oct 6, 2016

Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML

88 participants · First posted Jun 3, 2022

Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse.

100 participants · First posted Jun 18, 2021

Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML

24 participants · First posted Nov 7, 2024

FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

12 participants · First posted Sep 24, 2024

Page 1 of 2201